‘Important’ advance in tough-to-treat thyroid cancer

  data-srcset=
The disease control rate of 60% (versus 27% with placebo) is clinically meaningful in this heavily pretreated population. Photo: Pexels

(Ed Susman/ MedPage Today) –– Treatment with cabozantinib (Cabometyx) significantly improved progression-free survival (PFS) in patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer, an interim analysis of a phase III study found.

In the intent-to-treat population of COSMIC-311, median PFS was not reached with cabozantinib, as compared to 1.9 months with placebo (HR 0.22, 96% CI 0.13-0.36, P<0.0001), reported Marcia Brose, MD, PhD, of the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, at the virtual American Society of Clinical Oncology (ASCO) annual meeting. (…)

[button href=”https://www.medpagetoday.com/meetingcoverage/asco/93008″ arrow=”true” new_tab=”true”]read full story[/button]:

Posted in , ,

Categories

Categories